Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Key takeaways
- Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach Ardelyx logo Market Beat Thu, June 4, 2026 at 7:04 PM GMT+7 6 min read ARDX 3 mid-caps under $20 that Wall Street loves
- Chief Financial Officer Sue Hohenleitner said Ardelyx expects its two commercial products to generate more than $500 million in top-line revenue this year.
- → Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach Ardelyx logo Market Beat Thu, June 4, 2026 at 7:04 PM GMT+7 6 min read ARDX 3 mid-caps under $20 that Wall Street loves
Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
Chief Financial Officer Sue Hohenleitner said Ardelyx expects its two commercial products to generate more than $500 million in top-line revenue this year. IBSRELA, the company’s treatment for irritable bowel syndrome with constipation, or IBS-C, represents the largest portion of that outlook, with guidance of $410 million to $430 million. XPHOZAH, used for patients on dialysis with hyperphosphatemia, is expected to contribute $110 million to $120 million.